Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

被引：11

作者：

Bagnasco, Diego ^{[1
,2
,12
]}

Canevari, Rikki Frank ^{[2
,3
]}

Del Giacco, Stefano ^{[4
]}

Ferrucci, Silvia ^{[5
]}

Pigatto, Paolo ^{[6
]}

Castelnuovo, Paolo ^{[7
]}

Marseglia, Gian Luigi ^{[8
]}

Yalcin, Arzu Didem ^{[9
]}

Pelaia, Girolamo ^{[10
]}

Canonica, Giorgio Walter ^{[11
]}

机构：

[1] Univ Genoa, Dept Internal Med DIMI, Allergy & Resp Dis, Genoa, Italy

[2] IRCCS Policlin San Martino, Genoa, Italy

[3] Univ Genoa, Unit Otorhinolaryngol Head & Neck Surg, Genoa, Italy

[4] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy

[5] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

[6] IRCCS Ist Ortoped Galeazzi, Clin Dermatol, Milan, Italy

[7] Univ Insubria, Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Div Otorhinolaryngol, Varese, Italy

[8] Univ Pavia, Fdn IRCCS Policlin S Matteo, Pediat Clin, Pavia, Italy

[9] Univ Hlth Sci, Antalya Educ & Res Hosp, Dept Internal Med, Div Allergy & Immunol, Antalya, Turkey

[10] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy

[11] Personalized Med Ctr, Human Clin & Res Ctr, Asthma & Allergy, IRCCS, Milan, Italy

[12] Univ Genoa, Allergy & Resp Dis, IRCCS San Martino, Genoa, Italy

来源：

WORLD ALLERGY ORGANIZATION JOURNAL | 2022年 / 15卷 / 12期

关键词：

Severe asthma; Omalizumab; Cancer; Anti IgE; Monoclonal antibodies; MALIGNANCY;

D O I：

10.1016/j.waojou.2022.100721

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and sur-veillance analysis have consistently reported drug safety.

引用

页数：8

共 15 条

[1] No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study
Ali, Zarqa
Egeberg, Alexander
Thyssen, Jacob P.
Sorensen, Jennifer Astrup
Vestergaard, Christian
Thomsen, Simon Francis
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 746 - 748
[2] Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of "real-world' evidence
Bernstein, Jonathan A.
Kavati, Abhishek
Tharp, Michael D.
Ortiz, Benjamin
MacDonald, Karen
Denhaerynck, Kris
Abraham, Ivo
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (04) : 425 - 448
[3] Omalizumab and the risk of malignancy: Results from a pooled analysis
Busse, William
Buhl, Roland
Vidaurre, Carlos Fernandez
Blogg, Martin
Zhu, Jin
Eisner, Mark D.
Canvin, Janice
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (04) : 983 - U482
[4] Chicharro P, 2017, ACTAS DERMO-SIFILOGR, V108, P423, DOI 10.1016/j.ad.2016.07.018
[5] Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry-Some New Approaches
del Carmen Vennera, Maria
Perez de Llano, Luis
Bardagi, Santiago
Ausin, Pilar
Sanjuas, Carles
Gonzalez, Hector
Gullon, Jose A.
Martinez-Moragon, Eva
Carretero, Jose A.
Vera, Elisabet
Medina, Juan F.
Alvarez, Francisco J.
Entrenas, Luis M.
Padilla, Alicia
Irigaray, Rosa
Picado, Cesar
[J]. JOURNAL OF ASTHMA, 2012, 49 (04) : 416 - 422
[6] Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study
Di Bona, Danilo
Fiorino, Irene
Taurino, Marialuisa
Frisenda, Flavia
Minenna, Elena
Pasculli, Carlo
Kourtis, Georgios
Rucco, Anna Simona
Nico, Andrea
Albanesi, Marcello
Giliberti, Lucia
D'Elia, Luciana
Caiaffa, Maria Filomena
Macchia, Luigi
[J]. RESPIRATORY MEDICINE, 2017, 130 : 55 - 60
[7] European Medical Agency, US
[8] FDA, FDA DRUG SAFETY COMM
[9] AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)
Ferastraoaru, D.
Bax, H. J.
Bergmann, C.
Capron, M.
Castells, M.
Dombrowicz, D.
Fiebiger, E.
Gould, H. J.
Hartmann, K.
Jappe, U.
Jordakieva, G.
Josephs, D. H.
Levi-Schaffer, F.
Mahler, V
Poli, A.
Rosenstreich, D.
Roth-Walter, F.
Shamji, M.
Steveling-Klein, E. H.
Turner, M. C.
Untersmayr, E.
Karagiannis, S. N.
Jensen-Jarolim, E.
[J]. CLINICAL AND TRANSLATIONAL ALLERGY, 2020, 10 (01)
[10] AllergoOncology - the impact of allergy in oncology: EAACI position paper
Jensen-Jarolim, E.
Bax, H. J.
Bianchini, R.
Capron, M.
Corrigan, C.
Castells, M.
Dombrowicz, D.
Daniels-Wells, T. R.
Fazekas, J.
Fiebiger, E.
Gatault, S.
Gould, H. J.
Janda, J.
Josephs, D. H.
Karagiannis, P.
Levi-Schaffer, F.
Meshcheryakova, A.
Mechtcheriakova, D.
Mekori, Y.
Mungenast, F.
Nigro, E. A.
Penichet, M. L.
Redegeld, F.
Saul, L.
Singer, J.
Spicer, J. F.
Siccardi, A. G.
Spillner, E.
Turner, M. C.
Untersmayr, E.
Vangelista, L.
Karagiannis, S. N.
[J]. ALLERGY, 2017, 72 (06) : 866 - 887

← 1 2 →